explore -WSS

explore

author：comprehensive 2025-09-27 19:38:12 - browse：94963

An experimental drug from Insmed Incorporated successfully reduced lung problems among patients with an airway disease in a closely watched Phase 3 trial, sending the company’s share price soaring early Tuesday.

The drug, brensocatib, reduced so-called pulmonary exacerbations by roughly 20% versus placebo in patients with bronchiectasis, hitting the trial’s primary endpoint. The trial, called the ASPEN study, tested two dosages of the drug, and the company said both significantly cut rates of pulmonary exacerbations.

Insmed shares more than doubled in pre-market trading. Analysts have forecasted that brensocatib could lead to billions of dollars in annual sales if approved.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Medicaid, Medicare dual

leisure time

WSS

Mindstrong's demise and the future of mental health care

Did you have Obamacare on your GOP debate bingo card?

Extreme heat events are a public health emergency

10 million people disenrolled from Medicaid over past six months

Medicare solvency divides Republicans at the presidential debate

How one patient went off dialysis — and others can too

Wikipedia

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Heart attack and stroke risk calculators need revising

Intercept Pharmaceuticals sells itself for less than $1 billion

Anesthesiologist group: stop taking Ozempic before surgery

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Trump demands the U.S. pay no more for drugs than other countries … again

HPV cancer vaccine study demonstrates efficacy

Sports medicine is finally prioritizing gender equality

Medicaid, Medicare dual

23andMe had bad news about my health. I wish a person had delivered it

Why do women spend more than men on medical expenses?

hotspot

Paxlovid should be available without a positive Covid test

A clever new way to fix Medicaid and graduate medical education

FDA seeks to regulate lab

Listen: Who gets the credit for GLP

Will General Catalyst be the first of many hospital takeovers?

Did you have Obamacare on your GOP debate bingo card?

leisure time

focus

leisure time

focus